RECOVERY - Antiviral and Immune Plasma Infrastructure Development

Rationale for not using a fixed price contract:

A fixed price mechanism is not appropriate for this requirement. Although certain elements of the requirement, such as equipment and subcontracts, can and will be procured on a fixed price basis, the complexities of providing personnel and services to enhance clinical research infrastructure are highly variable and dependent on too many external factors to accurately develop a fixed price estimate. For example, different clinical sites may have very different equipment and IT requirements thus the costs to fully develop the infrastructure at each site could vary greatly. Infrastructure and administrative costs could also fluctuate greatly depending on the number of patients anticipated at individual sites. Overall, the level of risk and number of uncertainties make a fixed price contract impractical and likely less cost effective than a cost-type arrangement.

This task order was awarded competitively under the existing multiple award contracts HHSN272200900001I/2I/3I.

THIS NOTICE IS PROVIDED FOR INFORMATION PURPOSES ONLY. THIS OPPORTUNITY IS AVAILABLE ONLY TO CONTRACTORS UNDER THE DIVISION OF CLINICAL RESEARCH HHSN27220090000XI CONTRACTS.

The anti-viral and immune plasma infrastructure development program is designed to identify and establish administrative and clinical research management services in-support-of research focused on the need for anti-viral and immune plasma therapy trials. There is a foreseen requirement of the NIAID Division of Clinical Research (DCR) to rapidly establish collaborations to coordinate clinical research in response to urgent influenza research demands of global importance and public health urgency. Initiating clinical trials in hospitalized adult and pediatric subjects in an expeditious fashion compliant with regulatory standards is critically important. Cooperation and collaboration among key partners is also critical to meeting timelines. The objective of this acquisition will be to provide the personnel, equipment, and logistical support necessary to allow the collaborating institutions to quickly expand their influenza research capabilities.